Completed PHASE2 INTERVENTIONAL 3-arm NCT01521585

A Phase II Safety and Tolerability Study With SEN0014196

A Double-blind, Placebo-controlled Study in Huntington's Disease Patients to Determine the Safety and Tolerability of SEN0014196

Sponsor: Siena Biotech S.p.A.

Conditions Huntington's Disease

Interventions Placebo SEN0014196

Updated 5 times since 2017 Last updated: Nov 24, 2015 Started: Nov 30, 2011 Primary completion: Oct 31, 2012 Completion: Oct 31, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Huntington's Disease and is currently completed. Siena Biotech S.p.A. leads this study, which shows 5 recorded versions since 2011 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Nov 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Siena Biotech S.p.A.

Data source: Siena Biotech S.p.A.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Münster, Germany